Nitto Denko Avecia Revenue and Competitors

Milford, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Nitto Denko Avecia's estimated annual revenue is currently $115.5M per year.(i)
  • Nitto Denko Avecia's estimated revenue per employee is $155,000

Employee Data

  • Nitto Denko Avecia has 745 Employees.(i)
  • Nitto Denko Avecia grew their employee count by -1% last year.

Nitto Denko Avecia's People

NameTitleEmail/Phone
1
VP Business DevelopmentReveal Email/Phone
2
SVP, Regulatory and QualityReveal Email/Phone
3
Head Strategic SourcingReveal Email/Phone
4
SVP Human Resources; Board DirectorsReveal Email/Phone
5
Director QualityReveal Email/Phone
6
Senior Director Project ManagementReveal Email/Phone
7
Senior Director Process DevelopmentReveal Email/Phone
8
Associate Director Supply ChainReveal Email/Phone
9
Director, Analytical DevelopmentReveal Email/Phone
10
Director Business DevelopmentReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M20%N/AN/A
#3
$5.1M336%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
$5.4M353%N/AN/A
#10
$1.6M100%N/AN/A
Add Company

What Is Nitto Denko Avecia?

Nitto Denko Avecia is the largest oligonucleotide manufacturer in the world and continues to play an integral role in advancing the oligo therapeutic market. With over 20 years of experience and over 1,000 sequences manufactured, we fulfill our client's needs for pre-clinical, clinical, and launched products. With production capacity in FDA- audited facilities near Boston, MA, and Cincinnati, OH, we produce a novel class of active pharmaceutical ingredients (APIs) -- oligonucleotides -- used by pharmaceutical and biotechnology companies to develop drug treatments for a variety of health indications. In addition to our pre-clinical and CGMP oligo manufacturing capability, we leverage our wealth of expertise to offer a portfolio of services that includes Analytical Development, Process Development, and Quality Control testing.

keywords:Biotechnology,Cleantech,Finance,Healthcare,Pharmaceuticals,Wind Power

N/A

Total Funding

745

Number of Employees

$115.5M

Revenue (est)

-1%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Nitto Denko Avecia News

2022-04-19 - Oligonucleotide Synthesis Market Size, Outlook And Forecast ...

... Thermo Fisher Scientific, Bioautomation, Agilent Technologies, Eurogentec, GE Healthcare, LGC Biosearch Technologies, Nitto Denko Avecia.

2022-04-19 - Oligonucleotide Synthesis Market Size, Scope And Outlook ...

... Technologies Inc., Eurogentec S.A., General Electric Company, Thermo Fisher Scientific Biosearch Technologies, Nitto Denko Avecia Inc.

2022-04-17 - Oligonucleotides Market Size, Outlook And Forecast ...

... Sigma-aldrich, Eurofins Genomics, L.G.C Biosearch Technologies, Eurogentec S.A, Nitto Denko Avecia Inc, GenScript, BBI Life Sciences, GeneDesign.

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$224.8M89211%N/A
#2
$161.4M96121%N/A
#3
$161.4M96121%N/A
#4
$151M9746%N/A
#5
$497.2M10065%N/A